Open Innovation is a must, not a choice.
‘Hanmi Open Innovation Forum’ is held every year.
This year’s forum was held to contribute to expanding new drug
development through a win-win approach with Korean bio-ventures,
academic communities, research institutes, etc.,
who hold promising technologies.
Through Open Innovation Forums, Hanmi aims to give shape to diverse forms
of cooperation with industries, academics and research institutes,
while strengthening Hanmi’s pipeline.
1st HANMI OPEN INNOVATION FORUM2016
Session 1 : Establishment of a healthy win-win ecosystem through Open Innovation (Chair : Professor at College of Medicine, University of Ulsan, Dong-ho Lee)
Hanmi Open Innovation Forum
(Vice President of Hanmi, Jeewoong Son)
Examining cases of Open Innovation among recent new drug developments, Son shared ideas and experiences about key success factors. In addition, he proposed the establishment of an innovative ecosystem for the Korea’s growth into a pharmaceutical power, and explained Hanmi’s future R&D strategies.
Biocon : The Target Factory
(Professor at Seoul National University. Sung-hoon Kim)
SNU’s Medicinal Bioconvergence Research Center (Biocon, started in 2010) has developed ‘Target Factory’, a platform that combines stages from fundamental research to new drug development for candidate substances, making it possible to develop time and cost efficient drugs.
Open Innovation : National OncoVenture Model
(Head of National OncoVenture, Young-hwan Park)
Park emphasized that Open Innovation is a must, not a choice, considering the wide range of oncology drugs being developed around the world and the trends in treating cancers that cannot be sufficiently treated with monotherapies is shifting to dual, triple or combination therapies.
Open Innovation from the Bio-tech Perspective
(CEO of Bridge Biotherapeutics, Inc., Jung-gyu Lee)
Lee defined the three key factors that must be considered when establishing Open Innovation strategies as Invention, Intelligence and Interaction, and advised that Open Innovation can be successful only when these 3Is are well-combined.
Session 2 : Efforts of research institutes and companies for Open Innovation (Chair : Vice President of Hanmi, Jeewoong Son / CEO of Bridge Biotherapeutics Inc., Jung-gyu Lee)
Academic Drug Discovery
(Head of Research Center, KIST, Tae-bo Sim)
Sim introduced currently on-going studies in the quest for new low molecular weight organic compounds that inhibit cancer-causing proteins, and research for candidate substances. Protein kinase plays an important role in signaling pathways, and certain hyper-activated kinases by mutation, etc. causes various diseases such as cancer, inflammation, etc.
Open Innovation of LegoChem
(CEO of LegoChemBio, Yong-zu Kim)
Referring to some of LegoChemBio’s successful cases of technology transfer, Kim introduced the most suitable technology transfer model for Korea. Kim also advised that innovation gaps and patent cliffs multinational pharmaceutical companies are currently facing will offer boundless opportunities for ventures competent in early development.
Open Innovation of AptaBio
(CEO of AptaBio, Sung-hwan Moon)
Moon introduced NOX (NADPH oxidase) inhibitor, a reactive oxygen species controlling platform technology that can be used in the treatment of diabetes complications occurring in 70-90% of patients suffering from diabetes for more than 10 years.